Search Results
Your search for ,dUe matches 5584 pages
Showing 801 - 850T-DXd Shows High Intracranial Response Rate in Patients With Active Brain Metastases From HER2-Positive Breast Cancer
In the investigator-initiated, prospective, open-label, single-arm phase II TUXEDO-1 study conducted among patients with newly diagnosed or progressive brain metastases from HER2-positive breast cancer, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) yielded responses according...
Low-Dose Decitabine and Azacitidine in Lower-Risk MDS
As reported in NEJM Evidence by Sasaki et al, extended follow-up of a phase II trial showed good outcomes with low doses of the hypomethylating agents decitabine and azacitidine in previously untreated patients with lower-risk myelodysplastic syndromes (MDS). Study Details The study included 113...
FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients With Beta-Thalassemia Who Require Regular Blood Transfusions
On August 17, the U.S. Food and Drug Administration (FDA) approved betibeglogene autotemcel (Zynteglo), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. “[This] approval is an important...
Pralsetinib Achieves Tissue-Agnostic Benefits for Patients With RET Fusion–Positive Cancers
The highly selective RET inhibitor pralsetinib was well tolerated and demonstrated robust, durable responses in patients with RET fusion–positive cancers regardless of tumor type, according to results from the international phase I/II ARROW trial. Results from the trial were published in Nature...
A Surgical Oncologist From Afghanistan Discusses the Challenges of Delivering Cancer Care in a War-Torn Nation
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Ahmad Bashir Barekzai, MD, FACS, Consultant Surgical Oncologist at Ali Abad Teaching Hospital, an affiliated hospital to Kabul University of Medical Science, Kabul,...
Relationship Between Polypharmacy and Frailty Among Older Adults With Blood Cancers
A new study published by Hshieh et al in JNCCN–Journal of the National Comprehensive Cancer Network suggests a new way for hematologic oncologists to protect older patients from the risks of medication interactions. As part of the Older Adult Hematologic Malignancies Program, gerontology...
INTRIGUE Trial: Second-Line Ripretinib vs Sunitinib in Advanced GIST
As reported in the Journal of Clinical Oncology by Bauer et al, the phase III INTRIGUE trial showed no significant progression-free survival benefit with second-line ripretinib vs sunitinib in imatinib-pretreated patients with gastrointestinal stromal tumor (GIST), including among patients with KIT ...
Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study
Researchers from Japan recently reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1–positive unresectable locally advanced non–small cell lung cancer (NSCLC) without chemotherapy met its primary endpoint with...
Disparities in the Diagnosis of Lung Cancer Among Younger vs Older Adults
Younger patients with lung cancer are significantly more likely than older patients to be diagnosed with later stages of disease, illustrating the need to develop strategies to increase the early detection of lung cancer among younger patients who are currently ineligible for lung cancer screening. ...
Cancer Knows No Borders
This is a critical time for cancer research and cancer care across the world, and the cancer community has clearly highlighted the need for greater and more equitable international collaboration. Addressing the global cancer challenge is a significant undertaking, and it has become more urgent as ...
MOUNTAINEER: Tucatinib Plus Trastuzumab Active in Metastatic Colorectal Cancer
In the phase II MOUNTAINEER trial, tucatinib in combination with trastuzumab produced durable responses in patients with previously treated HER2-positive metastatic colorectal cancer. The late-breaking data were presented at the European Society for Medical Oncology (ESMO) World Congress on...
COLUMBUS Trial 5-Year Update: Encorafenib/Binimetinib vs Vemurafenib or Encorafenib in Advanced BRAF V600–Mutant Melanoma
In a 5-year update of part 1 of the phase III COLUMBUS trial reported in the Journal of Clinical Oncology, Dummer et al found a continued benefit of encorafenib plus binimetinib vs vemurafenib in patients with advanced BRAF V600–mutant melanoma. The trial supported the June 2018 approval of...
MRD-Adapted Study of Elotuzumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Without Transplantation Intent
In a phase II trial reported in JAMA Oncology, Derman et al found that a measurable residual disease (MRD)-adapted strategy with elotuzumab (Elo) plus carfilzomib, lenalidomide, and dexamethasone (KRd) was associated with high rates of stringent complete response and MRD-negative status in patients ...
Media Emphasis on Urinary Symptoms May Delay Diagnosis of Early Prostate Cancer
According to Cancer Research UK, over 52,000 men are diagnosed with prostate cancer each year in the UK, and there are more than 12,000 deaths. Over three-quarters (78%) of men diagnosed with the disease survive for over 10 years, but this proportion has barely changed over the past decade in the...
Talazoparib Plus Avelumab in Recurrent Mismatch Repair–Proficient Endometrial Cancer
In a phase II trial reported in JAMA Oncology, Konstantinopoulos et al found that the combination of talazoparib and avelumab was active in patients with recurrent mismatch repair–proficient endometrial cancer. Study Details In the U.S. multicenter study, 35 evaluable women with measurable disease, ...
Enzalutamide in Advanced Androgen Receptor–Positive Salivary Gland Cancer
In a phase II trial (Alliance A091404) reported in the Journal of Clinical Oncology, Ho et al found that enzalutamide showed some activity in advanced androgen receptor–positive salivary gland cancer but failed to meet the predefined criterion for a successful strategy. Study Details In the...
Study Could Lead to Better Education and Treatment of Sexual Health for Patients With Breast Cancer
A study released by the University of Colorado Cancer Center showed that more than 70% of patients with breast cancer have reported changes that affect their sexual health during and beyond treatment. The study was published by Huynh et al in the Annals of Surgical Oncology. Study Background “More...
Lenvatinib Plus Pembrolizumab for Advanced Melanoma Progressing on PD-1/PD-L1 Inhibitor Therapy
In the phase II LEAP-004 trial reported in Journal of Clinical Oncology, Arance et al found that the combination of lenvatinib and pembrolizumab was active in patients with advanced melanoma with confirmed progression on PD-1/PD-L1 inhibitors as monotherapy or in combination with other agents. As...
New Study Shows Options for Older Patients With Liver Cancer
Physicians and researchers from UK HealthCare's Transplant Center and the University of Kentucky Markey Cancer Center conducted a study of patients over age 70 with hepatocellular carcinoma to examine how the outcomes of ablative treatments compare to liver transplants. The findings were published...
Survey Reveals That Most Americans Are Not Concerned About Getting Lung Cancer
A recent survey shows that only 40% of Americans are concerned that they might get lung cancer, and only about one in five have talked to their doctor about their risk for the disease, despite lung cancer being the leading cause of cancer deaths in the United States. The 2022 Lung Health Barometer, ...
Oral Paclitaxel Plus P-Glycoprotein Pump Inhibitor Encequidar vs Intravenous Paclitaxel in Metastatic Breast Cancer
In a Latin American phase III trial reported in the Journal of Clinical Oncology, Hope S. Rugo, MD, and colleagues found that oral paclitaxel with the P-glycoprotein pump inhibitor encequidar produced a higher response rate and trends toward better survival outcomes vs intravenous (IV) paclitaxel...
Zandelisib in Continuous or Intermittent Dosing Schedules With or Without Rituximab for Relapsed or Refractory B-Cell Malignancies
In a first-in-patients phase Ib study reported in The Lancet Oncology, John M. Pagel, MD, PhD, and colleagues identified the safety profiles of the PI3Kδ inhibitor zandelisib given in intermittent vs continuous dosing schedules with or without rituximab in patients with relapsed of refractory...
Study Examines Role of Per- and Polyfluoroalkyl Substances in Development of Cancer, Health-Care Costs
Daily exposure to a class of chemicals used in the production of many household items may lead to cancer, thyroid disease, and childhood obesity, a new study published by Obsekov et al in the journal Exposure and Health showed. The resulting economic burden is estimated to cost Americans a minimum...
KEYNOTE-355: Overall Survival With the Addition of Pembrolizumab to Chemotherapy in Advanced Triple-Negative Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, and colleagues, the phase III KEYNOTE-355 trial has shown improved overall survival with the addition of pembrolizumab to chemotherapy in previously untreated patients with advanced triple-negative breast cancer with a...
ECHELON-1 Trial: Brentuximab Vedotin With Chemotherapy Offers Survival Benefit in Stage III or IV Hodgkin Lymphoma
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (a regimen known as A+AVD) significantly reduced the risk of mortality vs standard treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with previously untreated stage III or IV classical Hodgkin...
Hematology Highlights From ASCO 2022
A multitude of presentations were available to attendees at the 2022 ASCO Annual Meeting, including hundreds in the hematologic malignancies tracks. In addition to coverage in The ASCO Post of the major news stories at the meeting, here we offer summaries of additional studies of special interest...
Researchers Discover Protein That May Be Associated With Better Prognosis for Patients With Ovarian Cancer
Researchers have discovered that a protein associated with metabolism—and formerly recognized as a potential therapeutic target for ovarian cancer—may instead be associated with a better prognosis for patients with the malignancy. In a report published by Clemente et al in Cancer Research...
Survey Finds More Than 80% of Patients With Cancer and Survivors Say Copay Assistance Programs Help Them Afford Their Prescription Drugs
A new Survivor Views survey from the American Cancer Society Cancer Action Network (ACS CAN) showed that a majority of respondents (83%) who had applied to a copay assistance program and were accepted said the assistance enables them to get the medication they otherwise couldn’t afford. However,...
Adjuvant Everolimus Narrowly Misses Statistical Significance in RCC, Except for Very High–Risk Patients
In the phase III EVEREST trial, adjuvant everolimus improved median recurrence-free survival in patients with resected renal cell carcinoma (RCC), but this finding failed to be statistically significant in the total study population of 1,499 patients, according to a prespecified boundary. However,...
Addition of Ribociclib to Letrozole Improves Survival in Women With HR-Positive, HER2-Negative Advanced Breast Cancer
As reported in The New England Journal of Medicine by Gabriel N. Hortobagyi, MD, of the Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, and colleagues, the protocol-specified final overall survival analysis of the phase III MONALEESA-2 trial has shown a significant...
Eprenetapopt/Azacitidine Maintenance After Allogeneic HSCT for TP53-Mutant AML and MDS
In a phase II trial reported in the Journal of Clinical Oncology, Mishra et al found that maintenance treatment with the first-in-class small-molecule p53 reactivator eprenetapopt plus azacitidine following allogeneic hematopoietic stem cell transplantation (HSCT) was associated with “encouraging”...
Addition of Trabectedin to Doxorubicin in the First-Line Treatment of Advanced Leiomyosarcoma
In the French phase III LMS-04 trial reported in The Lancet Oncology, Pautier et al found that the addition of trabectedin to doxorubicin significantly prolonged progression-free survival as first-line treatment for patients with unresectable or metastatic leiomyosarcoma. Study Details In the...
Adagrasib in Previously Treated Patients With KRAS G12C–Mutated Advanced NSCLC
As reported in The New England Journal of Medicine by Pasi A. Jänne, MD, PhD, and colleagues, findings in a phase II cohort of the multicohort KRYSTAL-1 phase I/II study indicate that the KRAS G12C inhibitor adagrasib showed activity in previously treated patients with unresectable or metastatic...
Second-Line Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Large B-Cell Lymphoma Not Intended for HSCT
As reported in The Lancet Oncology by Sehgal et al, the phase II PILOT trial showed that the autologous, CD19-directed chimeric antigen receptor (CAR) T-cell product lisocabtagene maraleucel produced a high response rate in the second-line treatment of patients with relapsed or refractory large...
Deciphering the Elusive Origin and Pathways of Brain Metastases
The effective treatment of patients with brain metastases is an unmet need because, until fairly recently, patients with brain metastases were excluded from clinical trials of systemic therapies. However, the emergence of molecular targeted therapies has allowed a new treatment approach in patients ...
LuPSMA Improves Progression-Free Survival vs Cabazitaxel in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) achieved longer progression-free survival with fewer toxicities compared with cabazitaxel in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer whose disease...
President Biden Appoints Cancer Panel Members, and Cancer Cabinet Unveils Priority Actions
On July 13, President Joe Biden announced his intent to appoint Mitchel Berger, MD; Carol Brown, MD; and Elizabeth M. Jaffee, MD, to the President’s Cancer Panel. The three are distinguished members of the scientific, research, and public health communities appointed by the President to advise him...
Immune Checkpoint Inhibitors for Solid Tumors in Kidney Transplant Recipients With Maintained Immunosuppression
In an Australian phase I study reported in The Lancet Oncology, Carroll et al found that maintaining baseline immunosuppression in kidney transplant recipients receiving immune checkpoint inhibitor treatment for advanced solid tumors did not appear to increase the risk of irretrievable allograft...
Poziotinib Shows Activity in EGFR Exon 20–Mutant NSCLC, With Efficacy Dependent on Insertion Location
A phase II clinical trial of poziotinib for patients with non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 mutations found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may ...
Phase III Trial of Cabozantinib and Atezolizumab vs Sorafenib in Advanced Hepatocellular Carcinoma
As reported in The Lancet Oncology by Robin Kate Kelley, MD, and colleagues, the phase III COSMIC-312 trial has shown improved progression-free survival with cabozantinib plus atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma; interim analysis of overall survival showed...
History of Radiation Oncology in the United States
Part 1 of this two-part report described the beginnings of radiation oncology in the United States, including many of the field’s early pioneers and the rise of associated professional societies. In part 2, we will consider the advances in technology and biology that are the foundation of modern...
Shaping the Future of Cancer Care: The Value of Managing Aggregated Data From Patients’ Online Communities
In 2021, more than 1.9 million people in the United States were estimated to be diagnosed with cancer, and that number continues to increase yearly. Medical research is critical in prolonging survival and improving the quantity and quality of life of patients. Cancer research is one of the most...
First Randomized Chemotherapy Study in Relapsed or Refractory Ewing Sarcoma Reports Modest Gains in Survival With High-Dose Ifosfamide
High-dose ifosfamide extended event-free and overall survival in patients with recurrent or primary refractory Ewing sarcoma compared with other commonly used chemotherapy regimens, according to the results of a randomized trial reported at the 2022 ASCO Annual Meeting by lead author Martin...
Phase III Trial Reports Quizartinib Doubles Overall Survival in FLT3-ITD–Positive AML
A new treatment option has doubled overall survival for a difficult-to-treat subset of patients with acute myeloid leukemia (AML), according to data presented during the Presidential Symposium at the European Hematology Association (EHA) 2022 Congress in Vienna.1 Findings from the phase III...
Inspired by the TV Show M*A*S*H, Lori Wilson, MD, FACS, Achieves Many Firsts as a Leader in Oncology
Lori Wilson, MD, FACS, Chief of Surgical Oncology, Associate Dean of Faculty Development and Diversity, and former Program Director of the General Surgical Residency at Howard University Hospital, is the first woman to hold the position of Division Chief as well as the first tenured Professor of...
New Study: Patients Report Increased Likelihood to Enroll in Decentralized Clinical Trials
A new article published by Adams et al in JAMA Network Open details the potential benefits of using technology to increase patient participation in cancer clinical trials. In a survey of nearly 1,200 patients with cancer and survivors, more than 80% said they would be willing to use remote...
Addition of Atezolizumab to Neoadjuvant Anti-HER2 Therapy and Chemotherapy in HER2-Positive Breast Cancer: IMpassion050
As reported in the Journal of Clinical Oncology by Jens Huober, MD, and colleagues, the phase III IMpassion050 trial showed no significant improvement in pathologic complete response rate with the addition of atezolizumab to neoadjuvant pertuzumab/trastuzumab and chemotherapy in patients with...
Outcomes of the SARS–CoV-2 Omicron Variant Outbreak Among European Patients With Cancer
In an analysis from the retrospective OnCovid registry study reported in The Lancet Oncology, David J. Pinato, PhD, and colleagues detailed outcomes of the SARS–CoV-2 omicron variant outbreak among European patients with cancer. Study Details The analysis included 3,473 patients with cancer from...
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer
New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at Stanford University School of Medicine in California, who described the promising ...
Addition of Enzalutamide to Active Surveillance in Low- or Intermediate-Risk Localized Prostate Cancer
As reported in JAMA Oncology by Neal D. Shore, MD, FACS, and colleagues, the phase II ENACT trial has shown a reduced risk of disease progression with the addition of enzalutamide to active surveillance in patients with low- or intermediate-risk localized prostate cancer. Study Details In the...
